Our science

Publications and presentations

Filter content:

X-Linked Retinitis Pigmentosa

RPGR gene therapy and the Beacon clinical trials: Beacon Therapeutics Subretinal Gene Therapy laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP)

7 December 2024

Subretinal Gene Therapy laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP) Phase 2 Multicenter Study (DAWN): Preliminary Results

6 December 2024

Subretinal Gene Therapy Drug laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (SKYLINE): 24-Month Interim Safety Results

15 October 2024

Subretinal Gene Therapy Drug laru-zova (AGTC-501) for XLinked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (HORIZON): 36-Month Interim Results

19 September 2024

Subretinal laru-zova (AGTC-501) Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Phase 2 SKYLINE Trial

8 February 2024

Subretinal Gene Therapy Drug laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa Phase 2 Randomized, Controlled, Multicenter Clinical Trial (Skyline) 3-Month Results

3 December 2023

Corporate Presentations

RPGR gene therapy and the Beacon clinical trials: Beacon Therapeutics Subretinal Gene Therapy laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP)

7 December 2024